Quality of life in Parkinson’s disease improved by apomorphine pump: the OPTIPUMP cohort study
To report on OPTIPUMP, a cohort study, investigating the impact in real-life clinical settings of continuous subcutaneous apomorphine infusion (CSAI) on the quality of life (HRQoL) of patients with Parkinson’s disease. OPTIPUMP was a prospective, open-label, observational cohort study involving 30 i...
Gespeichert in:
| Veröffentlicht in: | Journal of neurology 2016-06, Vol.263 (6), p.1111-1119 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1119 |
|---|---|
| container_issue | 6 |
| container_start_page | 1111 |
| container_title | Journal of neurology |
| container_volume | 263 |
| creator | Drapier, Sophie Eusebio, Alexandre Degos, Bertrand Vérin, Marc Durif, Franck Azulay, Jean Philippe Viallet, François Rouaud, Tiphaine Moreau, Caroline Defebvre, Luc Fraix, Valerie Tranchant, Christine Andre, Karine Courbon, Christine Brefel Roze, Emmanuel Devos, David |
| description | To report on OPTIPUMP, a cohort study, investigating the impact in real-life clinical settings of continuous subcutaneous apomorphine infusion (CSAI) on the quality of life (HRQoL) of patients with Parkinson’s disease. OPTIPUMP was a prospective, open-label, observational cohort study involving 30 investigational sites in France. CSAI was proposed as part of routine clinical care to patients aged ≥18 years, in absence of dementia, with a PD diagnosis and based on the presence of motor fluctuations not controlled by oral treatments. The impact of APO-pump on quality of life was evaluated as the difference in PDQ-39 scores between the initiation treatment and the follow-up visit after 6 months’ treatment. All adverse events were recorded. Hyper- and hypodopaminergic behavioral tolerance was assessed on the Ardouin Scale of Behavior in Parkinson’s Disease. Between September 2011 and January 2013, we enrolled 142 patients: 42 patients were withdrawn due to pump removal (33), death (4), lost of follow-up (4), no available data (1). 100 completed the study. At 6 months, their HRQoL had significantly improved (
p
= 0.011), as had their total UPDRS score (
p
|
| doi_str_mv | 10.1007/s00415-016-8106-3 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_01301510v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1794469958</sourcerecordid><originalsourceid>FETCH-LOGICAL-c439t-21bcebc84f6464636031c42fbe4ffb4237ed20619282da27b4f876639c28bd7d3</originalsourceid><addsrcrecordid>eNqFkc1u1DAUhS0EokPhAdggS2xgEbj-iWOzqyqglQZ1kNq1cRKbcUni1E4qzY7X4PV4EhylVAgJIS8s-3z3-F4fhJ4TeEMAqrcJgJOyACIKSUAU7AHaEM5oQXipHqINMA5FyUp-hJ6kdA0AMguP0RGtQCyHDfryeTadnw44ONx5Z7Ef8M7Eb35IYfj5_UfCrU_WpCz0Ywy3tsX1AZsx9CGOez9YPM79-A5Pe4svdpfnu6tPO9yEfYgTTtPcHp6iR850yT6724_R1Yf3l6dnxfbi4_npybZoOFNTQUnd2LqR3AmeFxPASMOpqy13ruaUVbalIIiikraGVjV3shKCqYbKuq1adoxer7570-kx-t7Egw7G67OTrV7ugDAgJYFbktlXK5snupltmnTvU2O7zgw2zEkTCVLkPwL5f7RSnAulygV9-Rd6HeY45KEXilVKKlpmiqxUE0NK0br7ZgnoJVW9ppr7FXpJVbNc8-LOea57295X_I4xA3QFUpaGrzb-8fQ_XX8ByJuq-A</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1793798925</pqid></control><display><type>article</type><title>Quality of life in Parkinson’s disease improved by apomorphine pump: the OPTIPUMP cohort study</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Drapier, Sophie ; Eusebio, Alexandre ; Degos, Bertrand ; Vérin, Marc ; Durif, Franck ; Azulay, Jean Philippe ; Viallet, François ; Rouaud, Tiphaine ; Moreau, Caroline ; Defebvre, Luc ; Fraix, Valerie ; Tranchant, Christine ; Andre, Karine ; Courbon, Christine Brefel ; Roze, Emmanuel ; Devos, David</creator><creatorcontrib>Drapier, Sophie ; Eusebio, Alexandre ; Degos, Bertrand ; Vérin, Marc ; Durif, Franck ; Azulay, Jean Philippe ; Viallet, François ; Rouaud, Tiphaine ; Moreau, Caroline ; Defebvre, Luc ; Fraix, Valerie ; Tranchant, Christine ; Andre, Karine ; Courbon, Christine Brefel ; Roze, Emmanuel ; Devos, David</creatorcontrib><description>To report on OPTIPUMP, a cohort study, investigating the impact in real-life clinical settings of continuous subcutaneous apomorphine infusion (CSAI) on the quality of life (HRQoL) of patients with Parkinson’s disease. OPTIPUMP was a prospective, open-label, observational cohort study involving 30 investigational sites in France. CSAI was proposed as part of routine clinical care to patients aged ≥18 years, in absence of dementia, with a PD diagnosis and based on the presence of motor fluctuations not controlled by oral treatments. The impact of APO-pump on quality of life was evaluated as the difference in PDQ-39 scores between the initiation treatment and the follow-up visit after 6 months’ treatment. All adverse events were recorded. Hyper- and hypodopaminergic behavioral tolerance was assessed on the Ardouin Scale of Behavior in Parkinson’s Disease. Between September 2011 and January 2013, we enrolled 142 patients: 42 patients were withdrawn due to pump removal (33), death (4), lost of follow-up (4), no available data (1). 100 completed the study. At 6 months, their HRQoL had significantly improved (
p
= 0.011), as had their total UPDRS score (
p
< 0.001). Regarding the safety profile, Ardouin scale scores indicated that their hyperdopaminergic behaviors had not increased. CSAI had a favorable impact on HRQoL, with benefits outweighing risks. The analysis of the withdrawn patients highlights the heterogeneity of the use of the pump having an impact on its efficacy and tolerability.</description><identifier>ISSN: 0340-5354</identifier><identifier>EISSN: 1432-1459</identifier><identifier>DOI: 10.1007/s00415-016-8106-3</identifier><identifier>PMID: 27060084</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Aged ; Antiparkinson Agents - administration & dosage ; Antiparkinson Agents - adverse effects ; Apomorphine - administration & dosage ; Apomorphine - adverse effects ; Cohort analysis ; Dopamine Agonists - administration & dosage ; Dopamine Agonists - adverse effects ; Female ; Follow-Up Studies ; France ; Hospitals ; Humans ; Infusion Pumps - adverse effects ; Infusions, Subcutaneous - adverse effects ; Life Sciences ; Male ; Medicine ; Medicine & Public Health ; Movement disorders ; Neurology ; Neuroradiology ; Neurosciences ; Original Communication ; Parkinson Disease - drug therapy ; Parkinson Disease - psychology ; Parkinson's disease ; Prospective Studies ; Quality of Life ; Treatment Outcome</subject><ispartof>Journal of neurology, 2016-06, Vol.263 (6), p.1111-1119</ispartof><rights>Springer-Verlag Berlin Heidelberg 2016</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c439t-21bcebc84f6464636031c42fbe4ffb4237ed20619282da27b4f876639c28bd7d3</citedby><cites>FETCH-LOGICAL-c439t-21bcebc84f6464636031c42fbe4ffb4237ed20619282da27b4f876639c28bd7d3</cites><orcidid>0000-0001-9727-3459 ; 0000-0002-5683-2709 ; 0009-0002-7262-2338 ; 0000-0002-2417-799X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00415-016-8106-3$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00415-016-8106-3$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>230,314,776,780,881,27903,27904,41467,42536,51298</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27060084$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://univ-rennes.hal.science/hal-01301510$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Drapier, Sophie</creatorcontrib><creatorcontrib>Eusebio, Alexandre</creatorcontrib><creatorcontrib>Degos, Bertrand</creatorcontrib><creatorcontrib>Vérin, Marc</creatorcontrib><creatorcontrib>Durif, Franck</creatorcontrib><creatorcontrib>Azulay, Jean Philippe</creatorcontrib><creatorcontrib>Viallet, François</creatorcontrib><creatorcontrib>Rouaud, Tiphaine</creatorcontrib><creatorcontrib>Moreau, Caroline</creatorcontrib><creatorcontrib>Defebvre, Luc</creatorcontrib><creatorcontrib>Fraix, Valerie</creatorcontrib><creatorcontrib>Tranchant, Christine</creatorcontrib><creatorcontrib>Andre, Karine</creatorcontrib><creatorcontrib>Courbon, Christine Brefel</creatorcontrib><creatorcontrib>Roze, Emmanuel</creatorcontrib><creatorcontrib>Devos, David</creatorcontrib><title>Quality of life in Parkinson’s disease improved by apomorphine pump: the OPTIPUMP cohort study</title><title>Journal of neurology</title><addtitle>J Neurol</addtitle><addtitle>J Neurol</addtitle><description>To report on OPTIPUMP, a cohort study, investigating the impact in real-life clinical settings of continuous subcutaneous apomorphine infusion (CSAI) on the quality of life (HRQoL) of patients with Parkinson’s disease. OPTIPUMP was a prospective, open-label, observational cohort study involving 30 investigational sites in France. CSAI was proposed as part of routine clinical care to patients aged ≥18 years, in absence of dementia, with a PD diagnosis and based on the presence of motor fluctuations not controlled by oral treatments. The impact of APO-pump on quality of life was evaluated as the difference in PDQ-39 scores between the initiation treatment and the follow-up visit after 6 months’ treatment. All adverse events were recorded. Hyper- and hypodopaminergic behavioral tolerance was assessed on the Ardouin Scale of Behavior in Parkinson’s Disease. Between September 2011 and January 2013, we enrolled 142 patients: 42 patients were withdrawn due to pump removal (33), death (4), lost of follow-up (4), no available data (1). 100 completed the study. At 6 months, their HRQoL had significantly improved (
p
= 0.011), as had their total UPDRS score (
p
< 0.001). Regarding the safety profile, Ardouin scale scores indicated that their hyperdopaminergic behaviors had not increased. CSAI had a favorable impact on HRQoL, with benefits outweighing risks. The analysis of the withdrawn patients highlights the heterogeneity of the use of the pump having an impact on its efficacy and tolerability.</description><subject>Aged</subject><subject>Antiparkinson Agents - administration & dosage</subject><subject>Antiparkinson Agents - adverse effects</subject><subject>Apomorphine - administration & dosage</subject><subject>Apomorphine - adverse effects</subject><subject>Cohort analysis</subject><subject>Dopamine Agonists - administration & dosage</subject><subject>Dopamine Agonists - adverse effects</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>France</subject><subject>Hospitals</subject><subject>Humans</subject><subject>Infusion Pumps - adverse effects</subject><subject>Infusions, Subcutaneous - adverse effects</subject><subject>Life Sciences</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Movement disorders</subject><subject>Neurology</subject><subject>Neuroradiology</subject><subject>Neurosciences</subject><subject>Original Communication</subject><subject>Parkinson Disease - drug therapy</subject><subject>Parkinson Disease - psychology</subject><subject>Parkinson's disease</subject><subject>Prospective Studies</subject><subject>Quality of Life</subject><subject>Treatment Outcome</subject><issn>0340-5354</issn><issn>1432-1459</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNqFkc1u1DAUhS0EokPhAdggS2xgEbj-iWOzqyqglQZ1kNq1cRKbcUni1E4qzY7X4PV4EhylVAgJIS8s-3z3-F4fhJ4TeEMAqrcJgJOyACIKSUAU7AHaEM5oQXipHqINMA5FyUp-hJ6kdA0AMguP0RGtQCyHDfryeTadnw44ONx5Z7Ef8M7Eb35IYfj5_UfCrU_WpCz0Ywy3tsX1AZsx9CGOez9YPM79-A5Pe4svdpfnu6tPO9yEfYgTTtPcHp6iR850yT6724_R1Yf3l6dnxfbi4_npybZoOFNTQUnd2LqR3AmeFxPASMOpqy13ruaUVbalIIiikraGVjV3shKCqYbKuq1adoxer7570-kx-t7Egw7G67OTrV7ugDAgJYFbktlXK5snupltmnTvU2O7zgw2zEkTCVLkPwL5f7RSnAulygV9-Rd6HeY45KEXilVKKlpmiqxUE0NK0br7ZgnoJVW9ppr7FXpJVbNc8-LOea57295X_I4xA3QFUpaGrzb-8fQ_XX8ByJuq-A</recordid><startdate>20160601</startdate><enddate>20160601</enddate><creator>Drapier, Sophie</creator><creator>Eusebio, Alexandre</creator><creator>Degos, Bertrand</creator><creator>Vérin, Marc</creator><creator>Durif, Franck</creator><creator>Azulay, Jean Philippe</creator><creator>Viallet, François</creator><creator>Rouaud, Tiphaine</creator><creator>Moreau, Caroline</creator><creator>Defebvre, Luc</creator><creator>Fraix, Valerie</creator><creator>Tranchant, Christine</creator><creator>Andre, Karine</creator><creator>Courbon, Christine Brefel</creator><creator>Roze, Emmanuel</creator><creator>Devos, David</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><general>Springer Verlag</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>1XC</scope><orcidid>https://orcid.org/0000-0001-9727-3459</orcidid><orcidid>https://orcid.org/0000-0002-5683-2709</orcidid><orcidid>https://orcid.org/0009-0002-7262-2338</orcidid><orcidid>https://orcid.org/0000-0002-2417-799X</orcidid></search><sort><creationdate>20160601</creationdate><title>Quality of life in Parkinson’s disease improved by apomorphine pump: the OPTIPUMP cohort study</title><author>Drapier, Sophie ; Eusebio, Alexandre ; Degos, Bertrand ; Vérin, Marc ; Durif, Franck ; Azulay, Jean Philippe ; Viallet, François ; Rouaud, Tiphaine ; Moreau, Caroline ; Defebvre, Luc ; Fraix, Valerie ; Tranchant, Christine ; Andre, Karine ; Courbon, Christine Brefel ; Roze, Emmanuel ; Devos, David</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c439t-21bcebc84f6464636031c42fbe4ffb4237ed20619282da27b4f876639c28bd7d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Aged</topic><topic>Antiparkinson Agents - administration & dosage</topic><topic>Antiparkinson Agents - adverse effects</topic><topic>Apomorphine - administration & dosage</topic><topic>Apomorphine - adverse effects</topic><topic>Cohort analysis</topic><topic>Dopamine Agonists - administration & dosage</topic><topic>Dopamine Agonists - adverse effects</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>France</topic><topic>Hospitals</topic><topic>Humans</topic><topic>Infusion Pumps - adverse effects</topic><topic>Infusions, Subcutaneous - adverse effects</topic><topic>Life Sciences</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Movement disorders</topic><topic>Neurology</topic><topic>Neuroradiology</topic><topic>Neurosciences</topic><topic>Original Communication</topic><topic>Parkinson Disease - drug therapy</topic><topic>Parkinson Disease - psychology</topic><topic>Parkinson's disease</topic><topic>Prospective Studies</topic><topic>Quality of Life</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Drapier, Sophie</creatorcontrib><creatorcontrib>Eusebio, Alexandre</creatorcontrib><creatorcontrib>Degos, Bertrand</creatorcontrib><creatorcontrib>Vérin, Marc</creatorcontrib><creatorcontrib>Durif, Franck</creatorcontrib><creatorcontrib>Azulay, Jean Philippe</creatorcontrib><creatorcontrib>Viallet, François</creatorcontrib><creatorcontrib>Rouaud, Tiphaine</creatorcontrib><creatorcontrib>Moreau, Caroline</creatorcontrib><creatorcontrib>Defebvre, Luc</creatorcontrib><creatorcontrib>Fraix, Valerie</creatorcontrib><creatorcontrib>Tranchant, Christine</creatorcontrib><creatorcontrib>Andre, Karine</creatorcontrib><creatorcontrib>Courbon, Christine Brefel</creatorcontrib><creatorcontrib>Roze, Emmanuel</creatorcontrib><creatorcontrib>Devos, David</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>Journal of neurology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Drapier, Sophie</au><au>Eusebio, Alexandre</au><au>Degos, Bertrand</au><au>Vérin, Marc</au><au>Durif, Franck</au><au>Azulay, Jean Philippe</au><au>Viallet, François</au><au>Rouaud, Tiphaine</au><au>Moreau, Caroline</au><au>Defebvre, Luc</au><au>Fraix, Valerie</au><au>Tranchant, Christine</au><au>Andre, Karine</au><au>Courbon, Christine Brefel</au><au>Roze, Emmanuel</au><au>Devos, David</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Quality of life in Parkinson’s disease improved by apomorphine pump: the OPTIPUMP cohort study</atitle><jtitle>Journal of neurology</jtitle><stitle>J Neurol</stitle><addtitle>J Neurol</addtitle><date>2016-06-01</date><risdate>2016</risdate><volume>263</volume><issue>6</issue><spage>1111</spage><epage>1119</epage><pages>1111-1119</pages><issn>0340-5354</issn><eissn>1432-1459</eissn><abstract>To report on OPTIPUMP, a cohort study, investigating the impact in real-life clinical settings of continuous subcutaneous apomorphine infusion (CSAI) on the quality of life (HRQoL) of patients with Parkinson’s disease. OPTIPUMP was a prospective, open-label, observational cohort study involving 30 investigational sites in France. CSAI was proposed as part of routine clinical care to patients aged ≥18 years, in absence of dementia, with a PD diagnosis and based on the presence of motor fluctuations not controlled by oral treatments. The impact of APO-pump on quality of life was evaluated as the difference in PDQ-39 scores between the initiation treatment and the follow-up visit after 6 months’ treatment. All adverse events were recorded. Hyper- and hypodopaminergic behavioral tolerance was assessed on the Ardouin Scale of Behavior in Parkinson’s Disease. Between September 2011 and January 2013, we enrolled 142 patients: 42 patients were withdrawn due to pump removal (33), death (4), lost of follow-up (4), no available data (1). 100 completed the study. At 6 months, their HRQoL had significantly improved (
p
= 0.011), as had their total UPDRS score (
p
< 0.001). Regarding the safety profile, Ardouin scale scores indicated that their hyperdopaminergic behaviors had not increased. CSAI had a favorable impact on HRQoL, with benefits outweighing risks. The analysis of the withdrawn patients highlights the heterogeneity of the use of the pump having an impact on its efficacy and tolerability.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>27060084</pmid><doi>10.1007/s00415-016-8106-3</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0001-9727-3459</orcidid><orcidid>https://orcid.org/0000-0002-5683-2709</orcidid><orcidid>https://orcid.org/0009-0002-7262-2338</orcidid><orcidid>https://orcid.org/0000-0002-2417-799X</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0340-5354 |
| ispartof | Journal of neurology, 2016-06, Vol.263 (6), p.1111-1119 |
| issn | 0340-5354 1432-1459 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_hal_01301510v1 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Aged Antiparkinson Agents - administration & dosage Antiparkinson Agents - adverse effects Apomorphine - administration & dosage Apomorphine - adverse effects Cohort analysis Dopamine Agonists - administration & dosage Dopamine Agonists - adverse effects Female Follow-Up Studies France Hospitals Humans Infusion Pumps - adverse effects Infusions, Subcutaneous - adverse effects Life Sciences Male Medicine Medicine & Public Health Movement disorders Neurology Neuroradiology Neurosciences Original Communication Parkinson Disease - drug therapy Parkinson Disease - psychology Parkinson's disease Prospective Studies Quality of Life Treatment Outcome |
| title | Quality of life in Parkinson’s disease improved by apomorphine pump: the OPTIPUMP cohort study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T16%3A23%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Quality%20of%20life%20in%20Parkinson%E2%80%99s%20disease%20improved%20by%20apomorphine%20pump:%20the%20OPTIPUMP%20cohort%20study&rft.jtitle=Journal%20of%20neurology&rft.au=Drapier,%20Sophie&rft.date=2016-06-01&rft.volume=263&rft.issue=6&rft.spage=1111&rft.epage=1119&rft.pages=1111-1119&rft.issn=0340-5354&rft.eissn=1432-1459&rft_id=info:doi/10.1007/s00415-016-8106-3&rft_dat=%3Cproquest_hal_p%3E1794469958%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1793798925&rft_id=info:pmid/27060084&rfr_iscdi=true |